Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 11—November 2017
Research Letter

Mycobacterium shimoidei, a Rare Pulmonary Pathogen, Queensland, Australia

Timothy M. BairdComments to Author , Robyn Carter, Geoffrey Eather, and Rachel Thomson
Author affiliations: Princess Alexandra Hospital, Brisbane, Queensland, Australia (T.M. Baird, G. Eather); Metro South Clinical Tuberculosis Service, Brisbane (T.M. Baird, G. Eather, R. Thomson); Greenslopes Private Hospital, Brisbane (R. Thomson); University of Queensland, Brisbane (R. Thomson); Royal Brisbane and Womens Hospital, Brisbane (R. Carter)

Main Article


Clinical characteristics, treatment, and outcomes of Mycobacterium shimoidei isolates, Queensland, Australia*

Specimen (isolates) Age, y/sex Significant Signs/ symptoms Radiology Concurrent conditions Management (time) Outcome
Sp and Br (×4) 60/M Likely C, Sp, WL Cavities, nodule COPD, asthma Observed Stable
LTis (×1) 56/M Likely Died Unknown Unknown None Died
Sp (×1) 75/F Likely C, Sp, WL Cavities, nodules COPD, HF, AF, GERD None Died of other cause
Sp (×3) 72/M Likely C, D, WL Cavity, nodules COPD, bronchiectasis, IHD Observed Died of lung disease
LTis (×1) 62/F Likely C, WL, NS Cavity None INH, RFP, PZA, EMB (6 mo) Stable
Sp (×2) 68/M Likely C, Sp, H, WL, Fa Cavities, consolidation COPD, aspergillus, HTN CLA, MFX, SMX (12 mo) Improved
Sp and Br (×4) 70/M Likely C, Sp, CP Cavities Lung cancer, COPD, bronchiectasis CLA, RIF, EMB (12 mo) Died of lung disease
LTis (×1) 77/F Likely C, WL, Fa Cavity, nodules COPD, GERD CLA, RFP, EMB (18 mo) Improved
Sp (×3) 68/M Likely C, Sp, WL Cavity, consolidation COPD, RA, anemia Observed Stable
Br (×1) 76/M Possibly D, WL Nodules COPD, anemia None Unknown
Br (×1) 84/M Possibly C, Sp Mass, effusion Lung cancer, GERD Observed Died of lung disease
Sp (×1) 84/M Possibly C, D, Fa Consolidation COPD, bronchiectasis Observed Improved
Sp (×1) 29/M Possibly C, D, WL Nodules CF, bronchiectasis AMK, CFX, AZA, CFZ (24 mo) Improved
Sp (×1) 74/F Possibly C, Sp Nodules, consolidation Bronchiectasis Observed Improved
Sp (×5) 84/F Possibly C, Sp, H, WL Nodules Bronchiectasis, type 2 diabetes, HTN CLA (2 mo) Improved
Sp (×1) 58/M Possibly C, Sp Normal Obesity, HTN Observed Stable
Sp (×1) 57/M Unlikely Unknown Unknown Unknown Unknown Unknown
LTis (×1) 55/F Unlikely Unknown Unknown Unknown Unknown Unknown
Sp (×1) 67/M Unlikely Unknown Unknown Unknown Unknown Unknown
Sp (×1) 60/M Unlikely C, D Normal Asthma None Unknown
Sp (×1) 59/F Unlikely C Normal Asthma, GERD None Unknown
Sp (×1) 73/M Unlikely Unknown Unknown Unknown Unknown Unknown
Sp (×1) 54/M Unlikely Unknown Unknown Unknown Unknown Unknown

*AF, atrial fibrillation; AMK, amikacin; AZA, azithromycin; Br, bronchoscopic washing; C, cough; CF, cystic fibrosis; CFX, cefoxitin; CFZ, clofazimine; CLA, clarithromycin; COPD, chronic obstructive pulmonary disease; CP, chest pain; D, dyspnea; EMB, ethambutol; Fa, fatigue; GERD, gastroesophageal reflux disease; H, hemoptysis; HF, heart failure; HTN, hypertension; IHD, ischemic heart disease; INH, isoniazid; LTis, lung tissue; MFX, moxifloxacin; NS, night sweats; PZA, pyrazinamide; RA, rheumatoid arthritis; RFP, rifampin; RIF, rifabutin; SMX, sulfamethoxazole, Sp, sputum; WL, weight loss.

Main Article

Page created: October 17, 2017
Page updated: October 17, 2017
Page reviewed: October 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.